Established by the renowned pharmacologist prof. Li dapeng, zhejiang kanglaite group Co., Ltd. is a pharmaceutical oriented transnational corporation which has several subsidiaries I. E. Zhejiang kanglaite pharmaceutical Co., Ltd., hangzhou laifute winery Co., Ltd., kanglaite USA inc., kanglaite Russia branch office. And zhejiang kanglaite pharmaceutical research and development Co., Ltd.

Zhejiang kanglaite pharmaceutical Co., Ltd. is a "state key high-tech enterprise" entitled by China's ministry of science & technology. Covering an area of 7 hectares and a total floor space of 28, 000 sq. M, the lvp production line and auxiliary equipment were totally introduced from Europe and USA. International GMP standard is strictly followed in production. There is over 550 staff and 65% are with university diploma. Our 32 regional offices in China offer a strong momentum in expanding domestic market. In China average annual turnover of kanglaite injection is between us$37-38 million.

As " state basic drug" and "state medical insurance drug", kanglaite injection (klt) is a novel dual-function, broad spectrum and molecular targeting anticancer agent with its active substance extracted from a medicinal herb "semen coicis" by state of the art technology. Klt has remarkable function in inhibiting and killing various cancer cells while strengthening immune function. In addition it has significant effectiveness in controlling cancerous pain, resisting cachexia, preventing cancer metastasis, improving and prolonging patient survival.

Experience from basic research and long term clinical application has shown that klt presents good effect in the treatment of cancers mainly at sites of lung, liver, breast, prostate and malignant lymphoma, etc. It has brought great benefits to over 700, 000 patients at 3, 000 hospitals after being launched in China in 1995.

Klt has 100% intellectual property. Its chemical component, process technology and application have obtained patent certificates from over 10 countries including China, USA, ec, Russia, Japan, Korea, etc. In 2001 FDA approved klt to start clinical trials in USA. Phase I trial was successfully completed and phase ii studies with 60 pancreatic cancer cases is now in progress. The Russian ministry of health issued registration certificate in December 2003. Currently registration is in progress in kingdom of Saudi arabia, India and Pakistan, etc. At the end of 2008 our company received GMP inspection by moh, ksa. In addition new pharmaceutical products such as "kanglaite soft capsule", "gingko leave soft capsule" and high-energy fat emulsion, etc. Have been added to the product catalogue in recent years.